Epigenetics: A primer for clinicians

Blood Reviews

Volumn 30, Issue 4, 2016, Pages 285-295

  Paluch, Benjamin E ^a   Naqash, Abdul R ^b   Brumberger, Zachary ^c   Nemeth, Michael J ^a   Griffiths, Elizabeth A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 Hydroxymethylcytosine (5HmC); 5 Methylcytosine (5mC); Cytosine phospho guanine (CpG); DNA methyltransferases (DNMTs); DNMT inhibitor (DNMTi); Hypomethylating agent (HMA); Ten eleven translocation (TET)

Indexed keywords

ABEXINOSTAT; AZACITIDINE; BELINOSTAT; CISPLATIN; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DECITABINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; ENTINOSTAT; GIVINOSTAT; GUADECITABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; JNJ 6481585; KHK 2375; MOCETINOSTAT; MOLIBRESIB; NUCLEOSIDE DERIVATIVE; NY ESO 1 ANTIGEN; PANOBINOSTAT; PINOMETOSTAT; PRACINOSTAT; QUISINOSTAT; RESMINOSTAT; RICOLINOSTAT; ROMIDEPSIN; RVX 000222; TAZEMETOSTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; YHI 1001;

ACUTE LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADVANCED CANCER; B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DIFFUSE LARGE B CELL LYMPHOMA; DNA ALKYLATION; DNA DAMAGE; DNA HYDROXYMETHYLATION; DNA METHYLATION; DNA MODIFICATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; EPIGENETICS; EPIGENOTYPE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENOTYPE; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; RENAL CELL CARCINOMA; REVIEW; SARCOMA; SMALL CELL LUNG CANCER; SOLID MALIGNANT NEOPLASM; THYMUS CANCER; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; CELL DIFFERENTIATION; GENETIC EPIGENESIS; GENETICS;

CELL DIFFERENTIATION; EPIGENESIS, GENETIC; HUMANS;

EID: 84960981464     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2016.02.002     Document Type: Review

References (248)

1. Hotchkiss, R.D., The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. J Biol Chem 175:1 (1948), 315–332.
2. Sober, H.A., Handbook of biochemistry. 2d ed., 1970, Cleveland, OH, Chemical Rubber Company.
3. Hall, R., The modified nucleosides in nucleic acids. 1972, Columbia University Press, New York.
4. Gruenbaum, Y., Stein, R., Cedar, H., Razin, A., Methylation of CpG sequences in eukaryotic DNA. FEBS Lett 124:1 (1981), 67–71.
5. Wen, L., Li, X., Yan, L., Tan, Y., Li, R., Zhao, Y., et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol, 15(3), 2014, R49.
6. Ehrlich, M., Gama-Sosa, M.A., Huang, L.H., Midgett, R.M., Kuo, K.C., McCune, R.A., et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 10:8 (1982), 2709–2721.
7. Lister, R., Ecker, J.R., Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res 19:6 (2009), 959–966.
8. Bestor, T.H., Ingram, V.M., Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. Proc Natl Acad Sci U S A 80:18 (1983), 5559–5563.
9. Hermann, A., Goyal, R., Jeltsch, A., The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem 279:46 (2004), 48350–48359.
10. Vilkaitis, G., Suetake, I., Klimasauskas, S., Tajima, S., Processive methylation of hemimethylated CpG sites by mouse Dnmt1 DNA methyltransferase. J Biol Chem 280:1 (2005), 64–72.
11. Okano, M., Xie, S., Li, E., Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19:3 (1998), 219–220.
12. Stein, R., Gruenbaum, Y., Pollack, Y., Razin, A., Cedar, H., Clonal inheritance of the pattern of DNA methylation in mouse cells. Proc Natl Acad Sci U S A 79:1 (1982), 61–65.
13. Gowher, H., Jeltsch, A., Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites. J Mol Biol 309:5 (2001), 1201–1208.
14. Yokochi, T., Robertson, K.D., Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 277:14 (2002), 11735–11745.
15. Fatemi, M., Hermann, A., Gowher, H., Jeltsch, A., Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem 269:20 (2002), 4981–4984.
16. Lin, I.G., Han, L., Taghva, A., O'Brien, L.E., Hsieh, C.L., Murine de novo methyltransferase Dnmt3a demonstrates strand asymmetry and site preference in the methylation of DNA in vitro. Mol Cell Biol 22:3 (2002), 704–723.
17. Howell, C.Y., Bestor, T.H., Ding, F., Latham, K.E., Mertineit, C., Trasler, J.M., et al. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. Cell 104:6 (2001), 829–838.
18. Bourc'his, D., Xu, G.L., Lin, C.S., Bollman, B., Bestor, T.H., Dnmt3L and the establishment of maternal genomic imprints. Science 294:5551 (2001), 2536–2539.
19. Hata, K., Okano, M., Lei, H., Li, E., Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 129:8 (2002), 1983–1993.
20. Saitou, M., Kagiwada, S., Kurimoto, K., Epigenetic reprogramming in mouse pre-implantation development and primordial germ cells. Development 139:1 (2012), 15–31.
21. Okano, M., Bell, D.W., Haber, D.A., Li, E., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:3 (1999), 247–257.
22. Oka, M., Rodic, N., Graddy, J., Chang, L.J., Terada, N., CpG sites preferentially methylated by Dnmt3a in vivo. J Biol Chem 281:15 (2006), 9901–9908.
23. Hattori, N., Abe, T., Hattori, N., Suzuki, M., Matsuyama, T., Yoshida, S., et al. Preference of DNA methyltransferases for CpG islands in mouse embryonic stem cells. Genome Res 14:9 (2004), 1733–1740.
24. Kriaucionis, S., Heintz, N., The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324:5929 (2009), 929–930.
25. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:5929 (2009), 930–935.
26. Lian, C.G., Xu, Y., Ceol, C., Wu, F., Larson, A., Dresser, K., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:6 (2012), 1135–1146.
27. Ito, S., D'Alessio, A.C., Taranova, O.V., Hong, K., Sowers, L.C., Zhang, Y., Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466:7310 (2010), 1129–1133.
28. Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42:4 (2011), 451–464.
29. Bannister, A.J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell Res 21:3 (2011), 381–395.
30. Zhou, V.W., Goren, A., Bernstein, B.E., Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:1 (2011), 7–18.
31. Jaenisch, R., Bird, A., Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33:Suppl (2003), 245–254.
32. Goldberg, A.D., Allis, C.D., Bernstein, E., Epigenetics: a landscape takes shape. Cell 128:4 (2007), 635–638.
33. Waddington, C.H., The epigenotype. 1942. Int J Epidemiol 41:1 (2012), 10–13.
34. Garcia-Bellido A. Genetic control of wing disc development in Drosophila. Ciba Found Symp 1975;0(29):161–82.
35. Russo, V.E.A., Martienssen, R.A., Riggs, A.D., Epigenetic mechanisms of gene regulation. 1996, Cold Spring Harbor Laboratory Press, New York.
36. Bird, A., Perceptions of epigenetics. Nature 447:7143 (2007), 396–398.
37. Turner, B.M., Defining an epigenetic code. Nat Cell Biol 9:1 (2007), 2–6.
38. Compere, S.J., Palmiter, R.D., DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells. Cell 25:1 (1981), 233–240.
39. Lee, Jeannie T., Bartolomei, Marisa S., X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 152:6 (2013), 1308–1323.
40. Bird, A.P., Gene number, noise reduction and biological complexity. Trends Genet 11:3 (1995), 94–100.
41. Harbers, K., Schnieke, A., Stuhlmann, H., Jahner, D., Jaenisch, R., DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. Proc Natl Acad Sci U S A 78:12 (1981), 7609–7613.
42. Widschwendter, M., Jiang, G., Woods, C., Muller, H.M., Fiegl, H., Goebel, G., et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 64:13 (2004), 4472–4480.
43. Robertson, K.D., DNA methylation and human disease. Nat Rev Genet 6:8 (2005), 597–610.
44. Yoder, J.A., Walsh, C.P., Bestor, T.H., Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13:8 (1997), 335–340.
45. Muntean, A.G., Hess, J.L., The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 7 (2012), 283–301.
46. Herman, J.G., Baylin, S.B., Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:21 (2003), 2042–2054.
47. Ramsahoye, B.H., Biniszkiewicz, D., Lyko, F., Clark, V., Bird, A.P., Jaenisch, R., Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 97:10 (2000), 5237–5242.
48. Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462:7271 (2009), 315–322.
49. Ichiyanagi, T., Ichiyanagi, K., Miyake, M., Sasaki, H., Accumulation and loss of asymmetric non-CpG methylation during male germ-cell development. Nucleic Acids Res 41:2 (2013), 738–745.
50. Smith, Z.D., Meissner, A., DNA methylation: roles in mammalian development. Nat Rev Genet 14:3 (2013), 204–220.
51. Shen, J.C., Rideout, W.M. 3rd, Jones, P.A., The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res 22:6 (1994), 972–976.
52. Cooper, D.N., Youssoufian, H., The CpG dinucleotide and human genetic disease. Hum Genet 78:2 (1988), 151–155.
53. Sommer, S.S., Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene. FASEB J 6:10 (1992), 2767–2774.
54. Rideout, W.M. 3rd, Coetzee, G.A., Olumi, A.F., Jones, P.A., 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249:4974 (1990), 1288–1290.
55. Saxonov, S., Berg, P., Brutlag, D.L., A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 103:5 (2006), 1412–1417.
56. Branciamore, S., Chen, Z.X., Riggs, A.D., Rodin, S.N., CpG island clusters and pro-epigenetic selection for CpGs in protein-coding exons of HOX and other transcription factors. Proc Natl Acad Sci U S A 107:35 (2010), 15485–15490.
57. Li, E., Bestor, T.H., Jaenisch, R., Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69:6 (1992), 915–926.
58. Lei, H., Oh, S.P., Okano, M., Juttermann, R., Goss, K.A., Jaenisch, R., et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 122:10 (1996), 3195–3205.
59. Lyko, F., Ramsahoye, B.H., Kashevsky, H., Tudor, M., Mastrangelo, M.A., Orr-Weaver, T.L., et al. Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila. Nat Genet 23:3 (1999), 363–366.
60. Robertson, K.D., DNA methylation and chromatin — unraveling the tangled web. Oncogene 21:35 (2002), 5361–5379.
61. Jones, P.A., Liang, G., Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 10:11 (2009), 805–811.
62. Penn, N.W., Suwalski, R., O'Riley, C., Bojanowski, K., Yura, R., The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J 126:4 (1972), 781–790.
63. Globisch, D., Münzel, M., Müller, M., Michalakis, S., Wagner, M., Koch, S., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One, 5(12), 2010, e15367.
64. Munzel, M., Globisch, D., Carell, T., 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 50:29 (2011), 6460–6468.
65. Bolton, W.D., Rice, D.C., Goodyear, A., Correa, A.M., Erasmus, J., Hofstetter, W., et al. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg 137:6 (2009), 1379–1387.
66. Tan, L., Shi, Y.G., Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139:11 (2012), 1895–1902.
67. Lopez, C.M., Lloyd, A.J., Leonard, K., Wilkinson, M.J., Differential effect of three base modifications on DNA thermostability revealed by high resolution melting. Anal Chem 84:17 (2012), 7336–7342.
68. Mendonca, A., Chang, E.H., Liu, W., Yuan, C., Hydroxymethylation of DNA influences nucleosomal conformation and stability in vitro. Biochim Biophys Acta 1839:11 (2014), 1323–1329.
69. Madzo, J., Liu, H., Rodriguez, A., Vasanthakumar, A., Sundaravel, S., Caces, D.B., et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep 6:1 (2014), 231–244.
70. Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 9:5 (2014), 1841–1855.
71. Moen, E.L., Mariani, C.J., Zullow, H., Jeff-Eke, M., Litwin, E., Nikitas, J.N., et al. New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol Rev 263:1 (2015), 36–49.
72. Huang, Y., Pastor, W.A., Shen, Y., Tahiliani, M., Liu, D.R., Rao, A., The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One, 5(1), 2010, e8888.
73. Nestor, C., Ruzov, A., Meehan, R., Dunican, D., Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. Biotechniques 48:4 (2010), 317–319.
74. Wanunu, M., Cohen-Karni, D., Johnson, R.R., Fields, L., Benner, J., Peterman, N., et al. Discrimination of methylcytosine from hydroxymethylcytosine in DNA molecules. J Am Chem Soc 133:3 (2011), 486–492.
75. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J., Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:6648 (1997), 251–260.
76. Turner, B.M., Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 12:2 (2005), 110–112.
77. Musselman, C.A., Lalonde, M.E., Cote, J., Kutateladze, T.G., Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol 19:12 (2012), 1218–1227.
78. Tarakhovsky, A., Tools and landscapes of epigenetics. Nat Immunol 11:7 (2010), 565–568.
79. Ruthenburg, A.J., Allis, C.D., Wysocka, J., Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25:1 (2007), 15–30.
80. Strahl, B.D., Allis, C.D., The language of covalent histone modifications. Nature 403:6765 (2000), 41–45.
81. Iwasaki W, Miya Y, Horikoshi N, Osakabe A, Taguchi H, Tachiwana H, et al. Contribution of histone N-terminal tails to the structure and stability of nucleosomes. FEBS Open Bio 2013;3(0):363–9.
82. Marx, J., Molecular biology. Protein tail modification opens way for gene activity. Science, 311(5762), 2006, 757.
83. Shogren-Knaak, M., Ishii, H., Sun, J.M., Pazin, M.J., Davie, J.R., Peterson, C.L., Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311:5762 (2006), 844–847.
84. Dhall, A., Wei, S., Fierz, B., Woodcock, C.L., Lee, T.H., Chatterjee, C., Sumoylated human histone H4 prevents chromatin compaction by inhibiting long-range internucleosomal interactions. J Biol Chem 289:49 (2014), 33827–33837.
85. Cedar, H., Bergman, Y., Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:5 (2009), 295–304.
86. Feng, Q., Zhang, Y., The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15:7 (2001), 827–832.
87. Li, E., Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 3:9 (2002), 662–673.
88. Glozak, M.A., Seto, E., Histone deacetylases and cancer. Oncogene 26:37 (2007), 5420–5432.
89. Haberland, M., Montgomery, R.L., Olson, E.N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:1 (2009), 32–42.
90. Holson, E.B., Schreiber, S.L., Chemoproteomics quantifies complexity. Nat Biotechnol 29:3 (2011), 235–236.
91. Bantscheff, M., Hopf, C., Savitski, M.M., Dittmann, A., Grandi, P., Michon, A.M., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29:3 (2011), 255–265.
92. Dekker, F.J., Haisma, H.J., Histone acetyl transferases as emerging drug targets. Drug Discov Today 14:19–20 (2009), 942–948.
93. Manzo, F., Tambaro, F.P., Mai, A., Altucci, L., Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 19:6 (2009), 761–774.
94. Copeland, R.A., Solomon, M.E., Richon, V.M., Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8:9 (2009), 724–732.
95. Yang, Y., Bedford, M.T., Protein arginine methyltransferases and cancer. Nat Rev Cancer 13:1 (2013), 37–50.
96. Kubicek, S., O'Sullivan, R.J., August, E.M., Hickey, E.R., Zhang, Q., Teodoro, M.L., et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25:3 (2007), 473–481.
97. Chang, Y., Ganesh, T., Horton, J.R., Spannhoff, A., Liu, J., Sun, A., et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol 400:1 (2010), 1–7.
98. Liu, F., Chen, X., Allali-Hassani, A., Quinn, A.M., Wigle, T.J., Wasney, G.A., et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem 53:15 (2010), 5844–5857.
99. Vedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, A., Labrie, V., et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7:8 (2011), 566–574.
100. Ferguson, A.D., Larsen, N.A., Howard, T., Pollard, H., Green, I., Grande, C., et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure 19:9 (2011), 1262–1273.
101. Sack, J.S., Thieffine, S., Bandiera, T., Fasolini, M., Duke, G.J., Jayaraman, L., et al. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem J 436:2 (2011), 331–339.
102. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Majer, C.R., Sneeringer, C.J., Song, J., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:1 (2011), 53–65.
103. Greiner, D., Bonaldi, T., Eskeland, R., Roemer, E., Imhof, A., Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 1:3 (2005), 143–145.
104. Smith, B.C., Denu, J.M., Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789:1 (2009), 45–57.
105. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., Schapira, M., Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:5 (2012), 384–400.
106. Hojfeldt, J.W., Agger, K., Helin, K., Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 12:12 (2013), 917–930.
107. Kooistra, S.M., Helin, K., Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13:5 (2012), 297–311.
108. Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:7 (2004), 941–953.
109. Lee, M.G., Wynder, C., Cooch, N., Shiekhattar, R., An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437:7057 (2005), 432–435.
110. Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T., Shi, Y., Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19:6 (2005), 857–864.
111. Klose, R.J., Kallin, E.M., Zhang, Y., JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7:9 (2006), 715–727.
112. Kahl, P., Gullotti, L., Heukamp, L.C., Wolf, S., Friedrichs, N., Vorreuther, R., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66:23 (2006), 11341–11347.
113. Heidenblad, M., Lindgren, D., Jonson, T., Liedberg, F., Veerla, S., Chebil, G., et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics, 1, 2008, 3.
114. Schulte, J.H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69:5 (2009), 2065–2071.
115. Lim, S., Janzer, A., Becker, A., Zimmer, A., Schule, R., Buettner, R., et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31:3 (2010), 512–520.
116. Hayami, S., Kelly, J.D., Cho, H.S., Yoshimatsu, M., Unoki, M., Tsunoda, T., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128:3 (2011), 574–586.
117. Kauffman, E.C., Robinson, B.D., Downes, M.J., Powell, L.G., Lee, M.M., Scherr, D.S., et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 50:12 (2011), 931–944.
118. Schmidt, D.M., McCafferty, D.G., trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46:14 (2007), 4408–4416.
119. Ueda, R., Suzuki, T., Mino, K., Tsumoto, H., Nakagawa, H., Hasegawa, M., et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 131:48 (2009), 17536–17537.
120. Culhane, J.C., Wang, D., Yen, P.M., Cole, P.A., Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 132:9 (2010), 3164–3176.
121. Mimasu, S., Umezawa, N., Sato, S., Higuchi, T., Umehara, T., Yokoyama, S., Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49:30 (2010), 6494–6503.
122. Binda, C., Valente, S., Romanenghi, M., Pilotto, S., Cirilli, R., Karytinos, A., et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc 132:19 (2010), 6827–6833.
123. Ogasawara, D., Suzuki, T., Mino, K., Ueda, R., Khan, M.N., Matsubara, T., et al. Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem 19:12 (2011), 3702–3708.
124. Benelkebir, H., Hodgkinson, C., Duriez, P.J., Hayden, A.L., Bulleid, R.A., Crabb, S.J., et al. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorg Med Chem 19:12 (2011), 3709–3716.
125. Willmann, D., Lim, S., Wetzel, S., Metzger, E., Jandausch, A., Wilk, W., et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer 131:11 (2012), 2704–2709.
126. Schmitt, M.L., Hauser, A.T., Carlino, L., Pippel, M., Schulz-Fincke, J., Metzger, E., et al. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. J Med Chem 56:18 (2013), 7334–7342.
127. Vianello, P., Botrugno, O.A., Cappa, A., Ciossani, G., Dessanti, P., Mai, A., et al. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. Eur J Med Chem 86 (2014), 352–363.
128. Pieroni, M., Annunziato, G., Azzali, E., Dessanti, P., Mercurio, C., Meroni, G., et al. Further insights into the SAR of alpha-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A. Eur J Med Chem 92 (2015), 377–386.
129. Schenk, T., Chen, W.C., Gollner, S., Howell, L., Jin, L., Hebestreit, K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18:4 (2012), 605–611.
130. Fiskus, W., Sharma, S., Shah, B., Portier, B.P., Devaraj, S.G., Liu, K., et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 28:11 (2014), 2155–2164.
131. Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M.E., Borchers, C.H., Tempst, P., et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439:7078 (2006), 811–816.
132. Rose, N.R., Ng, S.S., Mecinovic, J., Lienard, B.M., Bello, S.H., Sun, Z., et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem 51:22 (2008), 7053–7056.
133. King, O.N., Li, X.S., Sakurai, M., Kawamura, A., Rose, N.R., Ng, S.S., et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One, 5(11), 2010, e15535.
134. Luo, X., Liu, Y., Kubicek, S., Myllyharju, J., Tumber, A., Ng, S., et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc 133:24 (2011), 9451–9456.
135. Chang, K.H., King, O.N., Tumber, A., Woon, E.C., Heightman, T.D., McDonough, M.A., et al. Inhibition of histone demethylases by 4-carboxy-2,2′-bipyridyl compounds. ChemMedChem 6:5 (2011), 759–764.
136. Zeng, L., Li, J., Muller, M., Yan, S., Mujtaba, S., Pan, C., et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc 127:8 (2005), 2376–2377.
137. Pan, C., Mezei, M., Mujtaba, S., Muller, M., Zeng, L., Li, J., et al. Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor. J Med Chem 50:10 (2007), 2285–2288.
138. Borah, J.C., Mujtaba, S., Karakikes, I., Zeng, L., Muller, M., Patel, J., et al. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 18:4 (2011), 531–541.
139. Chung, C.W., Coste, H., White, J.H., Mirguet, O., Wilde, J., Gosmini, R.L., et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 54:11 (2011), 3827–3838.
140. Hammitzsch, A., Tallant, C., Fedorov, O., O'Mahony, A., Brennan, P.E., Hay, D.A., et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A 112:34 (2015), 10768–10773.
141. Hay, D.A., Fedorov, O., Martin, S., Singleton, D.C., Tallant, C., Wells, C., et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 136:26 (2014), 9308–9319.
142. Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W., et al. Suppression of inflammation by a synthetic histone mimic. Nature 468:7327 (2010), 1119–1123.
143. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., et al. Selective inhibition of BET bromodomains. Nature 468:7327 (2010), 1067–1073.
144. Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:6 (2011), 904–917.
145. Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J.H., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 19:22 (2013), 6183–6192.
146. Henssen, A., Thor, T., Odersky, A., Heukamp, L., El-Hindy, N., Beckers, A., et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4:11 (2013), 2080–2095.
147. Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 20:4 (2014), 912–925.
148. Venkataraman, S., Alimova, I., Balakrishnan, I., Harris, P., Birks, D.K., Griesinger, A., et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 5:9 (2014), 2355–2371.
149. Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele, D.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 108:40 (2011), 16669–16674.
150. Herrmann, H., Blatt, K., Shi, J., Gleixner, K.V., Cerny-Reiterer, S., Mullauer, L., et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget 3:12 (2012), 1588–1599.
151. Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478:7370 (2011), 529–533.
152. Fong, C.Y., Gilan, O., Lam, E.Y., Rubin, A.F., Ftouni, S., Tyler, D., et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525:7570 (2015), 538–542.
153. Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.S., Muhar, M., et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525:7570 (2015), 543–547.
154. Herold, J.M., Wigle, T.J., Norris, J.L., Lam, R., Korboukh, V.K., Gao, C., et al. Small-molecule ligands of methyl-lysine binding proteins. J Med Chem 54:7 (2011), 2504–2511.
155. James, L.I., Korboukh, V.K., Krichevsky, L., Baughman, B.M., Herold, J.M., Norris, J.L., et al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem 56:18 (2013), 7358–7371.
156. James, L.I., Barsyte-Lovejoy, D., Zhong, N., Krichevsky, L., Korboukh, V.K., Herold, J.M., et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol 9:3 (2013), 184–191.
157. Harrison, C., Epigenetic drugs: new modulators of readers and erasers. Nat Rev Drug Discov, 12(3), 2013, 188.
158. Knudson, A.G. Jr., Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:4 (1971), 820–823.
159. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:6 (2009), 1315–1325.
160. Cancer Genome Atlas Research N, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:22 (2013), 2059–2074.
161. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44:1 (2012), 23–31.
162. Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C., Majeti, R., Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 111:7 (2014), 2548–2553.
163. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506:7488 (2014), 328–333.
164. Jeong, M., Sun, D., Luo, M., Huang, Y., Challen, G.A., Rodriguez, B., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 46:1 (2014), 17–23.
165. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:25 (2010), 2424–2433.
166. Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:7 (2011), 1153–1158.
167. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:6 (2010), 553–567.
168. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:15 (2009), 3285–3291.
169. Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:1 (2009), 144–147.
170. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:7274 (2009), 739–744.
171. Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:2 (2010), 339–344.
172. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:3 (2010), 225–234.
173. Ward, P.S., Cross, J.R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R.L., et al. Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production. Oncogene 31:19 (2012), 2491–2498.
174. Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:1 (2011), 17–30.
175. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:14 (2010), 2348–2355.
176. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:22 (2010), 3636–3643.
177. Patel, K.P., Ravandi, F., Ma, D., Paladugu, A., Barkoh, B.A., Medeiros, L.J., et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135:1 (2011), 35–45.
178. Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:6132 (2013), 626–630.
179. de Botton S PD, Stein EM, DiNardo C, Fathi AT, Roboz GJ, et al., editor Clinical safety and activity of AG-120, a first-in-class potent inhibitor of the IDH1 mutant protein, in a phase I study of patients with advanced, IDH1-mutant hematological malignancies. 20th Congress of the European Hematology Association; 2015; Vienna, Austria2015.
180. DiNardo C SE, Altman JK, Collins R, DeAngelo DJ, Fathi AT, et al., editor AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase I study of IDH2 mutation-positive advanced hematologic malignancies. 20th Congress of the European Hematology Association; 2015; Vienna, Austria 2015.
181. Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:4 (2010), 605–613.
182. Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:1 (2010), 13–27.
183. Bullinger, L., Ehrich, M., Dohner, K., Schlenk, R.F., Dohner, H., Nelson, M.R., et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 115:3 (2010), 636–642.
184. Qu, Y., Lennartsson, A., Gaidzik, V.I., Deneberg, S., Karimi, M., Bengtzen, S., et al. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics 9:8 (2014), 1108–1119.
185. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 360:22 (2009), 2289–2301.
186. Tefferi, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Patnaik, M.M., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:7 (2009), 1343–1345.
187. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128:4 (2007), 683–692.
188. Sonnet, M., Claus, R., Becker, N., Zucknick, M., Petersen, J., Lipka, D.B., et al. Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Med, 6(4), 2014, 34.
189. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:3 (2009), 223–232.
190. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:8 (2006), 1794–1803.
191. Quintas-Cardama, A., Santos, F.P., Garcia-Manero, G., Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 7:8 (2010), 433–444.
192. Taylor, S.M., Jones, P.A., Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 162:3 (1982), 679–692.
193. Weisenberger, D.J., Velicescu, M., Cheng, J.C., Gonzales, F.A., Liang, G., Jones, P.A., Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2:1 (2004), 62–72.
194. Jones, P.A., Taylor, S.M., Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:1 (1980), 85–93.
195. Creusot, F., Acs, G., Christman, J.K., Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257:4 (1982), 2041–2048.
196. Christman, J.K., Mendelsohn, N., Herzog, D., Schneiderman, N., Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 43:2 (1983), 763–769.
197. Liu, Z., Liu, S., Xie, Z., Blum, W., Perrotti, D., Paschka, P., et al. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC–MS/MS method. Nucleic Acids Res, 35(5), 2007, e31.
198. Griffiths, E.A., Gore, S.D., DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 45:1 (2008), 23–30.
199. Fandy, T.E., Herman, J.G., Kerns, P., Jiemjit, A., Sugar, E.A., Choi, S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:13 (2009), 2764–2773.
200. Qin, T., Castoro, R., El Ahdab, S., Jelinek, J., Wang, X., Si, J., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One, 6(8), 2011, e23372.
201. Klco, J.M., Spencer, D.H., Lamprecht, T.L., Sarkaria, S.M., Wylie, T., Magrini, V., et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121:9 (2013), 1633–1643.
202. Meldi, K., Qin, T., Buchi, F., Droin, N., Sotzen, J., Micol, J.B., et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest 125:5 (2015), 1857–1872.
203. Akalin, A., Garrett-Bakelman, F.E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet, 8(6), 2012, e1002781.
204. Gore, S.D., Baylin, S., Sugar, E., Carraway, H., Miller, C.B., Carducci, M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:12 (2006), 6361–6369.
205. Daskalakis, M., Nguyen, T.T., Nguyen, C., Guldberg, P., Kohler, G., Wijermans, P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:8 (2002), 2957–2964.
206. Galm, O., Wilop, S., Luders, C., Jost, E., Gehbauer, G., Herman, J.G., et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 84:Suppl. 1 (2005), 39–46.
207. Esteller, M., Corn, P.G., Baylin, S.B., Herman, J.G., A gene hypermethylation profile of human cancer. Cancer Res 61:8 (2001), 3225–3229.
208. Schermelleh, L., Spada, F., Easwaran, H.P., Zolghadr, K., Margot, J.B., Cardoso, M.C., et al. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2:10 (2005), 751–756.
209. Santi, D.V., Norment, A., Garrett, C.E., Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 81:22 (1984), 6993–6997.
210. Gabbara, S., Bhagwat, A.S., The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307 (1995), 87–92.
211. Ferguson, A.T., Vertino, P.M., Spitzner, J.R., Baylin, S.B., Muller, M.T., Davidson, N.E., Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 272:51 (1997), 32260–32266.
212. Palii, S.S., Van Emburgh, B.O., Sankpal, U.T., Brown, K.D., Robertson, K.D., DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28:2 (2008), 752–771.
213. Hollenbach, P.W., Nguyen, A.N., Brady, H., Williams, M., Ning, Y., Richard, N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One, 5(2), 2010, e9001.
214. Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:5 (2004), 1635–1640.
215. Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21:3 (2012), 430–446.
216. Karpf, A.R., A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1:3 (2006), 116–120.
217. Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:11 (2008), 2542–2553.
218. Almstedt, M., Blagitko-Dorfs, N., Duque-Afonso, J., Karbach, J., Pfeifer, D., Jager, E., et al. The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 34:7 (2010), 899–905.
219. Bao, L., Dunham, K., Lucas, K., MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 60:9 (2011), 1299–1307.
220. Yang, D., Torres, C.M., Bardhan, K., Zimmerman, M., McGaha, T.L., Liu, K., Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 188:9 (2012), 4441–4449.
221. Konkankit, V.V., Kim, W., Koya, R.C., Eskin, A., Dam, M.A., Nelson, S., et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med, 9, 2011, 192.
222. Yee, C., Greenberg, P., Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2:6 (2002), 409–419.
223. De Smet, C., De Backer, O., Faraoni, I., Lurquin, C., Brasseur, F., Boon, T., The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93:14 (1996), 7149–7153.
224. De Smet, C., Lurquin, C., Lethe, B., Martelange, V., Boon, T., DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:11 (1999), 7327–7335.
225. Woloszynska-Read, A., Mhawech-Fauceglia, P., Yu, J., Odunsi, K., Karpf, A.R., Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 14:11 (2008), 3283–3290.
226. Srivastava, P., Paluch, B.E., Matsuzaki, J., James, S.R., Collamat-Lai, G., Karbach, J., et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 38:11 (2014), 1332–1341.
227. Coral, S., Parisi, G., Nicolay, H.J., Colizzi, F., Danielli, R., Fratta, E., et al. Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother 62:3 (2013), 605–614.
228. Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol 207:1 (2006), 58–66.
229. Navada, S.C., Steinmann, J., Lubbert, M., Silverman, L.R., Clinical development of demethylating agents in hematology. J Clin Invest 124:1 (2014), 40–46.
230. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:1 (2007), 31–39.
231. San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15:11 (2014), 1195–1206.
232. Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., Baylin, S.B., Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:1 (1999), 103–107.
233. Gore, S.D., Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2:Suppl. 1 (2005), S30–S35.
234. Prebet, T., Sun, Z., Figueroa, M.E., Ketterling, R., Melnick, A., Greenberg, P.L., et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 32:12 (2014), 1242–1248.
235. Fang, F., Munck, J., Tang, J., Taverna, P., Wang, Y., Miller, D.F., et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res 20:24 (2014), 6504–6516.
236. Kuang, Y., El-Khoueiry, A., Taverna, P., Ljungman, M., Neamati, N., Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol 9:9 (2015), 1799–1814.
237. Leshchenko, V.V., Kuo, P.Y., Jiang, Z., Weniger, M.A., Overbey, J., Dunleavy, K., et al. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget 6:29 (2015), 27332–27342.
238. Xia, C., Leon-Ferre, R., Laux, D., Deutsch, J., Smith, B.J., Frees, M., et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol 74:4 (2014), 691–697.
239. Vendetti, F.P., Topper, M., Huang, P., Dobromilskaya, I., Easwaran, H., Wrangle, J., et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 6:1 (2015), 56–70.
240. Benson, E.A., Skaar, T.C., Liu, Y., Nephew, K.P., Matei, D., Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. PLoS One, 10(10), 2015, e0141279.
241. Scandura, J.M., Roboz, G.J., Moh, M., Morawa, E., Brenet, F., Bose, J.R., et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118:6 (2011), 1472–1480.
242. Attman, E., Aittoniemi, J., Sinisalo, M., Vuento, R., Lyytikainen, O., Karki, T., et al. Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital. Leuk Lymphoma, 1–8, 2015.
243. Ranganathan, P., Yu, X., Santhanam, R., Hofstetter, J., Walker, A., Walsh, K., et al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125:17 (2015), 2689–2692.
244. Clozel, T., Yang, S., Elstrom, R.L., Tam, W., Martin, P., Kormaksson, M., et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3:9 (2013), 1002–1019.
245. Odunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E.W., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 104:31 (2007), 12837–12842.
246. Odunsi, K., Matsuzaki, J., James, S.R., Mhawech-Fauceglia, P., Tsuji, T., Miller, A., et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2:1 (2014), 37–49.
247. Wang, L., Amoozgar, Z., Huang, J., Saleh, M.H., Xing, D., Orsulic, S., et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunol Res 3:9 (2015), 1030–1041.
248. Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendetti, F., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4:11 (2013), 2067–2079.